Jgnatova G L, Antonov V N
Institute of additional professional education, South Ural state medical University, Ministry of health of the Russian Federation, Chelyabinsk, Russia.
Ter Arkh. 2018 Apr 19;90(3):47-52. doi: 10.26442/terarkh201890347-52.
The analysis of the dynamics of compliance in patients with chronic obstructive pulmonary disease (COPD) on a background of vaccination.
A total of 394 male patients are covered by this study. The main endpoints of observation are as follows: 1. To evaluate the effectiveness It's important the dynamics of scores for mMRC, FEV1, the number of exacerbations, hospitalizations, the number of pneumonia cases. 2. To assess compliance it's necessary to conduct a test for adherence to the Moriska-Green questionnaire. For vaccine prophylaxis, 13-valent conjugated pneumococcal vaccine Prevenar-13 and a 23-valent polysaccharide vaccine Pnevmo23 were used. The dynamics of changes in the parameters studied was evaluated within 4 years of the therapy initiation.
The inclusion of vaccine prophylaxis of PCV13 in the patient management plan allows to reduce a degree of dyspnea and stabilize the main functional parameters of the respiratory system not only in the short term, but also for at least next 4 years. PCV13 vaccination of can be considered as a basic therapy along with bronchodilator therapy. The use of vaccine prophylaxis PCV13 significantly increases the compliance and adherence of patients to a therapy.
The use of vaccine prophylaxis PKV13 significantly increases patients ' compliance and adherence to the therapy.
分析慢性阻塞性肺疾病（COPD）患者在接种疫苗背景下的依从性动态变化。
本研究共纳入394例男性患者。观察的主要终点如下：1. 评估有效性：评估mMRC评分、第一秒用力呼气容积（FEV1）、急性加重次数、住院次数、肺炎病例数的动态变化非常重要。2. 评估依从性：有必要进行Moriska-Green问卷依从性测试。疫苗预防采用13价肺炎球菌结合疫苗沛儿13（Prevenar-13）和23价肺炎球菌多糖疫苗纽莫法23（Pnevmo23）。在治疗开始后的4年内评估所研究参数的变化动态。
在患者管理计划中纳入PCV13疫苗预防不仅能在短期内减轻呼吸困难程度并稳定呼吸系统的主要功能参数，而且在至少接下来的4年中都能起到这样的作用。PCV13疫苗接种可被视为与支气管扩张剂治疗同样重要的基础治疗。使用PCV13疫苗预防可显著提高患者对治疗的依从性。
使用PKV13疫苗预防可显著提高患者对治疗的依从性。
